After Padcev combo’s major triumph, Merck’s Keytruda delivers partial win in bladder cancer

The combination of Merck's Keytruda and Pfizer and Astellas' Padcev recently made waves in bladder cancer—and the broader oncology world—by delivering a massive life-extension benefit against chemotherapy. Now, Merck can claim another positive readout for Keytruda in bladder cancer, although this one is short of a home run.